Comparative assessment in healthy male volunteers under fasting conditions of the absorption and pharmacokinetics of a test formulation of isotretinoin capsule against an innovator isotretinoin capsule in a pilot study

Single dose, crossover study design whereby each participant receives the test formulation of isotretinoin, 1 x 10 mg capsule on one occasion and the innovator formulation of isotretinoin, 1 x 10 mg capsule on one occasion. The intervention for this trial is the test formulation of isotretinoin. No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for the water consumed with each dose). Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after each dose. Bathroom visits will be supervised to ensure no unauthorized water or food intake and for personal safety. Participants will be confined at the Clinical Site for 12 hours prior to dosing to ensure compliance and for 24 hours after dosing. Participants will be monitored for adverse events throughout the study. Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 12 hours prior to dosing. Pre and post study laboratory tests will be completed to assess the health of the participants along with HIV, Hepatitis and drugs of abuse testing. Each dose will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure that the medication has been taken as directed. Each dose is separated by a one week washout period.